
Gene Editing Technology Developer

Located inEpigenic Therapeutics, Inc. in the Free Trade Zone No.1 Life Science Industrial Park, Pudong New Area, ShanghaiOn August 29, it was officially announced to be selected as "2024 Forbes Asia-Pacific 100 Most Promising Companies ListEpigenic, a cutting-edge biotechnology company dedicated to treating various diseases through epigenetic regulation and developing the next generation of gene modulation therapies.

The recently announced fourth "2024 Forbes Asia-Pacific 100 Most Promising Companies" list aims to showcase small and start-up companies in the Asia-Pacific region that have garnered significant investor attention. These 100 companies have demonstrated strong innovation capabilities, with business areas covering a wide range, from AI navigation systems for space exploration to cutting-edge cell therapies and advanced medical diagnostic technologies. The list includes companies from 16 countries and regions, spanning 10 industries including enterprise technology and robotics, finance, manufacturing, and energy. India tops the list with 20 companies, followed by Singapore (15), China (10), Japan (9), and Indonesia (8). Epigenic Therapeutics, Inc. has successfully been selected for the "2024 Forbes Asia-Pacific 100 Most Promising Companies" list due to its outstanding innovation capabilities and leading technology.

Epigenic stated that in the future, it will continue to conduct in-depth research in the life sciences field, continuously enhance its innovation capabilities, and is committed to providing safer and more effective treatment options for patients with chronic diseases. The company aims to maintain a leading position in the field of epigenetic therapies, offering more treatment choices to patients worldwide and promoting the widespread application of gene regulation therapies.
Epigenic is a cutting-edge biotechnology company dedicated to developing next-generation gene regulation therapies through epigenetic modulation for the treatment of various diseases. Founded in 2021 by a group of scientists specializing in gene editing technology and seasoned experts from the pharmaceutical development industry, the company has established a pipeline of multiple candidate products covering metabolic, cardiovascular, viral hepatitis, ophthalmology, and rare diseases.
About SimbayPark
Shanghai FT1 Life Science Park (abbreviation"Simbay Park, StarNorth · Free Trade Zone No.1") is located in the Waigaoqiao Bonded Area, the core of Shanghai's Pudong New Area Free Trade Zone. It is an innovative service-oriented characteristic industrial park under the StarNorth Group, focusing on the incubation, cultivation, and transformation of medical enterprises.The park relies on the unique "FTAs + bonded" outward-oriented economic regional advantages, and through gathering the whole industry chain service resources of CRO+CDMO+CSO+EHS in biopharmaceuticals, government innovation and entrepreneurship support policies, and numerous well-known investment institutions, provides enterprises with truly in-depth technical incubation in the medical industry. It also serves as a steward for the transformation of enterprise technology achievements, and strives to create an international biopharmaceutical industry innovation and entrepreneurship base.
